BLA 761324 · Genmab US, Inc.
Epkinly
Epcoritamab-Bysp · Subcutaneous · Bispecific CD20-directed CD3 T Cell Engager
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, May 19, 2023: To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 19, 2023
Approved uses
4
Original approval plus efficacy supplements
Registered trials
62
6 Phase 3, 35 recruiting
FAERS reports
1,338
1,237 serious, 442 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CYTOKINE RELEASE SYNDROME AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. Withhold EPKINLY until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.1) ] . Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life-threatening and fatal reactions, can occur with EPKINLY. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold EPKINLY until ICANS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 , 2.2 , 2.6) and Warnings and Precautions (5.2) ] . WARNING: CYTOKINE RELEASE...
What it is approved for
From the label in effect Jun 22, 2026.
EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). ( 1.2 ) As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. ( 1.2 ) 1.1 DLBCL and High-grade B-cell Lymphoma EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Follicular Lymphoma EPKINLY is indicated in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). EPKINLY is indicated as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
Mechanism: Epcoritamab-bysp is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and healthy B-lineage cells. In vitro, epcoritamab-bysp activated T-cells, caused the release of proinflammatory cytokines, and induced lysis of B-cells. In nonclinical studies, the combination of epcoritamab-bysp and rituximab resulted in both T-cell mediated cytotoxicity and natural killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC).
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2026 Supplement 10 · Efficacy OrphanLabelMedication GuideLetter
- Nov 18, 2025 Supplement 9 · Efficacy · priority review Breakthrough therapyOrphanLetterLabelMedication Guide
- Jun 26, 2024 Supplement 3 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- May 19, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
2 products under this application
- EPKINLY · EPCORITAMAB-BYSP 4MG/0.8ML · INJECTABLE, SUBCUTANEOUS · Prescription
- EPKINLY · EPCORITAMAB-BYSP 48MG/0.8ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Epcoritamab" as an intervention, any sponsor and status, largest first.
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaPivotal-lookingActive, not recruiting
GenmabIndustry
NCT06191744 · 1,095 participants · Start Feb 5, 2024 · Primary completion Nov 2037
Drug: Epcoritamab; Prednisone and 7 more · For: Follicular Lymphoma (FL)
Sites: Fresno, California; San Diego, California; Santa Barbara, California · 266 sites in all
- A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Pivotal-lookingActive, not recruiting
GenmabIndustry
NCT05578976 · 900 participants (planned) · Start Feb 8, 2023 · Primary completion Jun 2027
Drug: Epcoritamab; Cyclophosphamide and 4 more · For: Diffuse Large B-Cell Lymphoma
Sites: Tucson, Arizona; Yuma, Arizona; Little Rock, Arkansas · 331 sites in all
- First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaActive, not recruiting
GenmabIndustry
NCT03625037 · 666 participants · Start Jun 26, 2018 · Primary completion Jan 2029
Drug: Epcoritamab · For: DLBCL; High-grade B-cell Lymphoma (HGBCL); Primary Mediastinal Large B-cell Lymphoma (PMBCL) and 6 more
Sites: Phoenix, Arizona; San Francisco, California; Denver, Colorado · 85 sites in all
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular LymphomaPivotal-lookingActive, not recruiting
GenmabIndustry
NCT05409066 · 549 participants · Start Sep 20, 2022 · Primary completion Dec 2029
Drug: Epcoritamab; Rituximab and 1 more · For: Follicular Lymphoma (FL)
Sites: Tucson, Arizona; Little Rock, Arkansas; Berkeley, California · 273 sites in all
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)Active, not recruiting
GenmabIndustry
NCT04663347 · 543 participants · Start Nov 3, 2020 · Primary completion Sep 30, 2027
Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; rituximab and lenalidomide and 16 more · For: Diffuse Large B-Cell Lymphoma; Follicular Lymphoma
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 57 sites in all
- A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)Pivotal-lookingActive, not recruiting
GenmabIndustry
NCT04628494 · 483 participants · Start Jan 13, 2021 · Primary completion Oct 13, 2025
Drug: Epcoritamab; Investigator's Choice Chemotherapy · For: Diffuse Large B-cell Lymphoma
Sites: Indianapolis, Indiana; Lexington, Kentucky; Jackson, Michigan · 186 sites in all
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06090539 · 460 participants (planned) · Start Dec 29, 2023 · Primary completion Oct 28, 2027
Drug: BMS-986458; Rituximab and 4 more · For: Relapsed/Refractory Non-Hodgkin Lymphoma
Sites: Phoenix, Arizona; Duarte, California; Jacksonville, Florida · 76 sites in all
- A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaPivotal-lookingActive, not recruiting
GenmabIndustry
NCT06508658 · 379 participants · Start Aug 13, 2024 · Primary completion Mar 2028
Drug: Epcoritamab; Rituximab and 3 more · For: Diffuse Large B-Cell Lymphoma
Sites: Duarte, California; Los Angeles, California; Palm Springs, California · 176 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cytokine release syndrome463
- diffuse large b-cell lymphoma251
- diffuse large b-cell lymphoma refractory235
- pyrexia148
- immune effector cell-associated neurotoxicity syndrome108
- malignant neoplasm progression104
- neutrophil count decreased58
- cytomegalovirus infection reactivation56
- covid-1954
- platelet count decreased45
- hypogammaglobulinaemia43
- pneumonia39
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 104 |
| 2024 | 580 |
| 2025 | 410 |
| 2026 | 244 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Epkinly (Epcoritamab-Bysp)
2024 spending
$1.2M
Beneficiaries
n/a
32 claims
Per beneficiary
n/a
$16,388.47 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,185,684 |
Part B: Epkinly (Epcoritamab-Bysp) · HCPCS J9321
2024 spending
$53.6M
Beneficiaries
403
3,702 claims
Per beneficiary
$133,047
2024 ASP limit $54.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $53,618,014 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont C, Phillips T, Ghesquieres H, et al. · J Clin Oncol 2023 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Falchi L, Nijland M, Huang H, et al. · Lancet 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
Brody JD, Jørgensen J, Belada D, et al. · Blood 2025 · Clinical Trial, Phase II, Multicenter Study
- Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.
Linton KM, Vitolo U, Jurczak W, et al. · Lancet Haematol 2024 · Clinical Trial, Phase II, Multicenter Study
- Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.
Falchi L, Sureda A, Leppä S, et al. · Blood 2025 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.
Danilov AV, Kambhampati Thiruvengadam S, Linton K, et al. · Blood Adv 2025 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Genmab US, Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.